Clinical Trial Update: COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS

View source ↗

Summary

A Biogen-sponsored trial evaluating compliance with Avonex PS in patients with relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: COMPLETED